Figure 1From: Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer Immunological monitoring assay of T cell response to CDCA1, CDH3 and KIF20A in patient 8. (a) IFN-γ ELISPOT assay for CDCA1, CDH3 and KIF20A. (b) IFN-γ positive spots at several R/S ratio.Back to article page